PARIS--(EON: Enhanced Online News)--EOS imaging (Paris:EOSI)(Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announced it will exhibit its full EOSapps software suite at the upcoming American Academy of Orthopedic Surgeons (AAOS) Annual Meeting, being held March 14 – 18 in San Diego, California. The AAOS academic program also includes ten oral podium presentations featuring the EOS imaging technology and software solutions.
EOS imaging will particularly showcase hipEOS, a fully integrated pre-op and post-op 3D simulation and planning software which enables enhanced 3D personalized care for patients. hipEOS addresses several key areas of concern for total hip arthroplasty (THA):
- Prevention of implant wear, impingement and dislocation risks through personalized implant positioning rather than generic “safe zone” as well as incorporation of functional parameters from standing and seated exams.
- Prevention of leg length discrepancy, an important area of concern for patient satisfaction and one of the most common reasons for litigation, through the utilization of weight-bearing 3D data to plan length and position.
Marie Meynadier, CEO of EOS imaging, said: “We are pleased to see increasing acknowledgement in the orthopedic field of the value of EOS 3D imaging and planning, as compared to using higher cost, higher dose, supine CT scanning. The podium presentations highlighting EOS system and applications at this year’s AAOS, along with the significant increase in EOS-related publications in peer-reviewed journals in 2016, which doubled from 2015, support this momentum.”
EOS imaging will be onsite at Booth #4933 (Hall G), where the company will showcase the EOS low dose imaging system and its full suite of FDA cleared surgical planning EOSapps solutions, which includes hipEOS, along with spineEOS and kneeEOS. The EOSapps are online 3D surgical simulation and planning solutions, based on unbiased, weight-bearing EOS images and an accurate 2D/3D patient-specific data set.
In addition to the activities at its booth at AAOS, the Company is scheduled to present at the Canaccord Genuity Musculoskeletal Conference on March 14, 2017 at 10:30 am PST. The conference provides the opportunity for institutional investors to meet with the Company.
For more information, please visit www.eos-imaging.com.
EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.
EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI
About EOS imaging
EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system dedicated to osteoarticular pathologies and orthopaedics, as well as associated solutions. The Company is authorized to market in 51 countries, including the United States (FDA), Japan and the European Union (EC). The Group posted 2016 revenues of €30.8 million and employs 132 people at December 2016, including an R&D team of 43 engineers. The Group is based in Paris and has five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.